Zoetis (ZTS) Competitors $148.61 -1.42 (-0.95%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$148.57 -0.04 (-0.03%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ZTS vs. IDXX, MRK, PFE, BMY, RPRX, CORT, JAZZ, PRGO, SUPN, and PCRXShould you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include IDEXX Laboratories (IDXX), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), and Pacira BioSciences (PCRX). These companies are all part of the "medical" sector. Zoetis vs. Its Competitors IDEXX Laboratories Merck & Co., Inc. Pfizer Bristol Myers Squibb Royalty Pharma Corcept Therapeutics Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Zoetis (NYSE:ZTS) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations. Does the media refer more to ZTS or IDXX? In the previous week, Zoetis had 17 more articles in the media than IDEXX Laboratories. MarketBeat recorded 44 mentions for Zoetis and 27 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.36 beat Zoetis' score of 1.21 indicating that IDEXX Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 29 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 18 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ZTS or IDXX more profitable? Zoetis has a net margin of 27.12% compared to IDEXX Laboratories' net margin of 22.76%. IDEXX Laboratories' return on equity of 57.35% beat Zoetis' return on equity.Company Net Margins Return on Equity Return on Assets Zoetis27.12% 55.48% 19.14% IDEXX Laboratories 22.76%57.35%26.97% Do analysts recommend ZTS or IDXX? Zoetis presently has a consensus target price of $204.63, indicating a potential upside of 37.69%. IDEXX Laboratories has a consensus target price of $560.33, indicating a potential upside of 8.89%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than IDEXX Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zoetis 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.70IDEXX Laboratories 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has better earnings and valuation, ZTS or IDXX? Zoetis has higher revenue and earnings than IDEXX Laboratories. Zoetis is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZoetis$9.26B7.15$2.49B$5.5726.68IDEXX Laboratories$3.90B10.62$887.87M$10.8247.56 Do insiders and institutionals believe in ZTS or IDXX? 92.8% of Zoetis shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 1.0% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, ZTS or IDXX? Zoetis has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. SummaryIDEXX Laboratories beats Zoetis on 10 of the 16 factors compared between the two stocks. Get Zoetis News Delivered to You Automatically Sign up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZTS vs. The Competition Export to ExcelMetricZoetisMED IndustryMedical SectorNYSE ExchangeMarket Cap$66.16B$2.44B$5.53B$20.79BDividend Yield1.35%1.80%3.76%3.65%P/E Ratio26.689.0228.2627.58Price / Sales7.15557.90412.9970.58Price / Cash21.02161.4735.8522.27Price / Book14.065.008.114.66Net Income$2.49B$30.99M$3.25B$995.72M7 Day Performance-4.07%1.69%1.63%-0.30%1 Month Performance-5.50%10.07%7.62%4.91%1 Year Performance-16.78%0.90%32.74%11.21% Zoetis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZTSZoetis4.9571 of 5 stars$148.61-0.9%$204.63+37.7%-16.8%$66.16B$9.26B26.6813,800Trending NewsAnalyst DowngradeAnalyst RevisionIDXXIDEXX Laboratories3.5741 of 5 stars$531.74-0.3%$558.11+5.0%+9.9%$42.76B$3.93B49.1411,000Positive NewsAnalyst ForecastAnalyst RevisionMRKMerck & Co., Inc.4.9954 of 5 stars$83.72+0.4%$108.69+29.8%-36.4%$210.21B$64.17B12.1975,000Positive NewsAnalyst RevisionPFEPfizer4.9724 of 5 stars$25.36-1.2%$28.55+12.6%-18.4%$144.15B$62.46B18.3781,000Trending NewsBMYBristol Myers Squibb4.8206 of 5 stars$47.36+1.1%$57.69+21.8%+11.2%$96.38B$47.64B17.7434,100Trending NewsAnalyst RevisionRPRXRoyalty Pharma4.9701 of 5 stars$36.26+1.2%$48.33+33.3%+26.5%$20.39B$2.26B19.6080News CoveragePositive NewsDividend AnnouncementCORTCorcept Therapeutics4.8258 of 5 stars$72.78+1.2%$138.25+90.0%+109.1%$7.72B$675.04M62.74300Positive NewsJAZZJazz Pharmaceuticals4.8521 of 5 stars$111.47+1.1%$184.00+65.1%+3.5%$6.75B$4.06B14.862,800Positive NewsAnalyst ForecastPRGOPerrigo4.6757 of 5 stars$27.42-0.4%$33.00+20.4%-3.8%$3.77B$4.37B-20.938,379News CoveragePositive NewsSUPNSupernus Pharmaceuticals2.579 of 5 stars$33.95+2.5%$36.00+6.0%+6.9%$1.90B$661.82M30.59580News CoverageAnalyst DowngradePCRXPacira BioSciences3.2986 of 5 stars$23.33+1.9%$26.44+13.3%+11.5%$1.08B$700.97M-10.23720Positive NewsAnalyst Revision Related Companies and Tools Related Companies IDEXX Laboratories Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol Myers Squibb Alternatives Royalty Pharma Alternatives Corcept Therapeutics Alternatives Jazz Pharmaceuticals Alternatives Perrigo Alternatives Supernus Pharmaceuticals Alternatives Pacira BioSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZTS) was last updated on 7/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the sam...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSteve Jobs' Deathbed Secret Finally LeakedLeaked: Jobs’ Final Apple Project Exposed Bloomberg just leaked details of a secret project Steve Jobs set ...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zoetis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zoetis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
